BioCentury | Feb 8, 2020
Product Development

Coronavirus biology: where products in clinical testing intervene

The 13 therapies in clinical trials to treat coronavirus map to at least half a dozen mechanisms, intervening at three different steps in the viral cycle or manipulating different aspects of the host immune response....
BC Innovations | Dec 10, 2019
Emerging Company Profile

Zentalis debuts with trio of clinical oncology programs, $85M series C

Zentalis emerged from stealth Monday with an untranched and oversubscribed $85 million series C and three internally discovered clinical cancer candidates, with plans to begin pivotal testing by 2021. The C round syndicate includes Matrix...
BioCentury | Jan 5, 2019
Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
BC Week In Review | Aug 31, 2018
Financial News

China GL Capital claims 5% stake in U.K.'s Oxford BioDynamics

Epigenetic biomarker company Oxford BioDynamics plc (LSE:OBD) partnered with GL Capital Group to address demand for healthcare and personalized medicine in China. The Greater China healthcare-focused firm will act as the U.K.-based biotech's lead mainland...
BC Extra | Aug 22, 2018
Financial News

China's GL Capital claims 5% stake in U.K.'s Oxford BioDynamics

Epigenetic biomarker company Oxford BioDynamics plc (LSE:OBD) partnered with GL Capital Group to address demand for healthcare and personalized medicine in China. The Greater China healthcare-focused firm will act as the U.K.-based biotech's lead mainland...
BC Week In Review | Jun 29, 2018
Financial News

C-Bridge leads Nuance's series B

Nuance Biotech (Shanghai) Co. Ltd. (Shanghai, China) raised $20 million in a series B round led by C-Bridge Capital. Nuance is eligible to receive an additional $15 million from C-Bridge for acquiring new products. Nuance...
BC Extra | Jun 28, 2018
Financial News

C-Bridge leads Nuance's series B

Nuance Biotech (Shanghai) Co. Ltd. (Shanghai, China) raised $20 million in a series B round led by C-Bridge Capital. Nuance is eligible to receive an additional $15 million from C-Bridge for acquiring new products. Nuance...
BC Week In Review | Jun 26, 2018
Company News

Nuance gains Chinese rights to Pacira's Exparel

Pacira Pharmaceuticals Inc. (NASDAQ:PCRX) granted Nuance Biotech Co. Ltd. (Shanghai, China) exclusive rights to develop and commercialize Exparel bupivacaine in China. Pacira is to receive $3 million up front and is eligible for $55 million...
BC Week In Review | Dec 1, 2017
Company News

SciClone completes going private deal

A consortium of investors led by GL Capital and including Bank of China, CDH, Ascendent Capital Partners and Boying completed its acquisition of SciClone Pharmaceuticals Inc. for $11.18 per share in cash. The deal valued...
BC Week In Review | Aug 11, 2017
Clinical News

Soligenix begins Phase III of dusquetide to treat oral mucositis

Soligenix Inc. (NASDAQ:SNGX) began the Phase III IDR-OM-02 (DOM-INNATE) trial of dusquetide (SGX94, SGX942) to treat severe oral mucositis (OM) in about 190 patients undergoing chemoradiation therapy (CRT) for head and neck cancer. Patients receive...
Items per page:
1 - 10 of 375
BioCentury | Feb 8, 2020
Product Development

Coronavirus biology: where products in clinical testing intervene

The 13 therapies in clinical trials to treat coronavirus map to at least half a dozen mechanisms, intervening at three different steps in the viral cycle or manipulating different aspects of the host immune response....
BC Innovations | Dec 10, 2019
Emerging Company Profile

Zentalis debuts with trio of clinical oncology programs, $85M series C

Zentalis emerged from stealth Monday with an untranched and oversubscribed $85 million series C and three internally discovered clinical cancer candidates, with plans to begin pivotal testing by 2021. The C round syndicate includes Matrix...
BioCentury | Jan 5, 2019
Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
BC Week In Review | Aug 31, 2018
Financial News

China GL Capital claims 5% stake in U.K.'s Oxford BioDynamics

Epigenetic biomarker company Oxford BioDynamics plc (LSE:OBD) partnered with GL Capital Group to address demand for healthcare and personalized medicine in China. The Greater China healthcare-focused firm will act as the U.K.-based biotech's lead mainland...
BC Extra | Aug 22, 2018
Financial News

China's GL Capital claims 5% stake in U.K.'s Oxford BioDynamics

Epigenetic biomarker company Oxford BioDynamics plc (LSE:OBD) partnered with GL Capital Group to address demand for healthcare and personalized medicine in China. The Greater China healthcare-focused firm will act as the U.K.-based biotech's lead mainland...
BC Week In Review | Jun 29, 2018
Financial News

C-Bridge leads Nuance's series B

Nuance Biotech (Shanghai) Co. Ltd. (Shanghai, China) raised $20 million in a series B round led by C-Bridge Capital. Nuance is eligible to receive an additional $15 million from C-Bridge for acquiring new products. Nuance...
BC Extra | Jun 28, 2018
Financial News

C-Bridge leads Nuance's series B

Nuance Biotech (Shanghai) Co. Ltd. (Shanghai, China) raised $20 million in a series B round led by C-Bridge Capital. Nuance is eligible to receive an additional $15 million from C-Bridge for acquiring new products. Nuance...
BC Week In Review | Jun 26, 2018
Company News

Nuance gains Chinese rights to Pacira's Exparel

Pacira Pharmaceuticals Inc. (NASDAQ:PCRX) granted Nuance Biotech Co. Ltd. (Shanghai, China) exclusive rights to develop and commercialize Exparel bupivacaine in China. Pacira is to receive $3 million up front and is eligible for $55 million...
BC Week In Review | Dec 1, 2017
Company News

SciClone completes going private deal

A consortium of investors led by GL Capital and including Bank of China, CDH, Ascendent Capital Partners and Boying completed its acquisition of SciClone Pharmaceuticals Inc. for $11.18 per share in cash. The deal valued...
BC Week In Review | Aug 11, 2017
Clinical News

Soligenix begins Phase III of dusquetide to treat oral mucositis

Soligenix Inc. (NASDAQ:SNGX) began the Phase III IDR-OM-02 (DOM-INNATE) trial of dusquetide (SGX94, SGX942) to treat severe oral mucositis (OM) in about 190 patients undergoing chemoradiation therapy (CRT) for head and neck cancer. Patients receive...
Items per page:
1 - 10 of 375